NEUROTROPE, INC. (OTCMKTS:NTRPD) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03
|
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year |
On February 17, 2017, at a special meeting of stockholders (the
Special Meeting) of Neurotrope, Inc. (the
Company), the stockholders of the Company
approved an amendment to the Companys Articles of Incorporation
(the Charter), to be effective immediately, to
increase the number of authorized shares of our common stock to
150,000,000 shares. The amendment was filed with the Secretary of
State of the State of Nevada on February 24, 2017.
The amendment to the Charter is filed as Exhibit 3.1 to this
report and is incorporated by reference herein. The foregoing
summary of the amendment is qualified in its entirety by
reference to the full text of the Charter, as amended.
| Item 5.07. |
Submission of Matters to a Vote of Security Holders. |
(a)On February 17, 2017, the Company held the Special Meeting. As
of January 13, 2017, the record date for the Special Meeting,
there were 6,781,357 shares of our common stock outstanding and
entitled to vote. At the Special Meeting, the holders of
4,467,178 shares were present in person or represented by proxy,
which represented 65.874% of the total shares entitled to vote at
the Special Meeting.
(b)The following actions were taken at the Special Meeting:
| (1) |
The amendment to the Companys Charter to increase the number of authorized shares of our common stock to 150,000,000 shares, was approved, based on the following votes: |
| Votes For | Votes Against | Votes Abstain | Broker Non-Vote |
| 3,934,287 | 427,485 | 51,934 | 53,472 |
| (2) |
The adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1 was approved, based on the following votes: |
| Votes For | Votes Against | Votes Abstain | Broker Non-Vote |
| 3,940,257 | 462,720 | 64,200 |
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit | ||
| Number | Description | |
| 3.1 |
Neurotrope, Inc. Certificate of Amendment to Articles of Incorporation. |
About NEUROTROPE, INC. (OTCMKTS:NTRPD)
Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer’s disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients with AD. NEUROTROPE, INC. (OTCMKTS:NTRPD) Recent Trading Information
NEUROTROPE, INC. (OTCMKTS:NTRPD) closed its last trading session down -0.85 at 18.15 with 59,447 shares trading hands.
